Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01438775 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
A Phase 3 study, sponsored by Nymox Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 192
- Enrollment target
NCT01438775: Completed Phase 3 study, sponsored by Nymox Corporation.
NCT01438775 is a Phase 3 study that has completed, run by Nymox Corporation. The registered enrollment target is 192 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01438775, a Phase 3 study, has completed, sponsored by Nymox Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 192 participants
- Enrollment target
Study Summary
This study is designed to demonstrate the safety and efficacy of a second transrectal intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia (BPH) who previously received an injection of NX-1207 in an earlier U.S. clinical trial of NX-1207.
Primary Outcome
Safety parameters as determined by Adverse Events, clinical laboratory test results, vital signs, physical exam and electrocardiogram (ECG).
Interventions
- DRUG NX-1207
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 3 |
What the finished NCT01438775 record still lists
NCT01438775 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 1 intervention - of which NX-1207 is the first listed.
NCT01438775 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01438775 about?
NCT01438775 is a clinical study titled "Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)". This study is designed to demonstrate the safety and efficacy of a second transrectal intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia (BPH) who previously received an injection of NX-1207 in an earlier U.S. clinical trial of NX-1207.
What is the current status of trial NCT01438775?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 192 participants. The study started on 2011-09. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01438775?
The interventions under investigation include: NX-1207 (DRUG).
Who is sponsoring clinical trial NCT01438775?
This trial is sponsored by Nymox Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01438775's enrollment target sits among peer trials
192 1398th of 2000 higher than 599 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia